Dental Caries and GLP-1: A Growing Concern
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists, a type of medication used to treat type 2 diabetes and obesity, has brought a growing concern in the dental community. These medications, commonly prescribed drugs like Ozempic, have been linked to an increased risk of dental caries, a condition characterized by the breakdown of teeth due to acids produced by bacteria.
Understanding the Link between GLP-1 and Dental Caries
While the exact mechanism behind the link between GLP-1 and dental caries is not fully understood, research suggests that these medications can affect saliva production, which plays a crucial role in buffering acids and washing away bacteria. Reduced salivary flow can lead to an increased risk of dental caries, gum inflammation, and oral infections. Additionally, nausea and occasional vomiting associated with GLP-1 therapy can expose teeth to gastric acid, contributing to enamel erosion over time.
Oral Health Risks Associated with GLP-1 Medications
- Xerostomia (dry mouth) and halitosis (bad breath)
- Increased caries risk due to altered eating habits and reduced hydration
- Enamel erosion caused by exposure to gastric acid
- Tooth decay, sensitivity, and loss
- Impaired GLP-1 signaling, exacerbating glucotoxicity and lipotoxicity in individuals with diabetes or obesity
:max_bytes(150000):strip_icc()/toothdecay-ae5f1d34932c4aa68aa86fc8ed716877.jpg "GLP-1 Receptor Agonists and Oral Health: Essential Insights for ...")
